Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine - Wikidata - wikimedia - TriplyDB

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine

http://www.wikidata.org/entity/Q28478376

about

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.An update on pharmacotherapy for leishmaniasis Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers Cutaneous leishmaniasis: recent developments in diagnosis and management Quantification of Leishmania (Viannia) Kinetoplast DNA in Ulcers of Cutaneous Leishmaniasis Reveals Inter-site and Inter-sampling Variability in Parasite Load Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature.Duplex quantitative Reverse-Transcriptase PCR for simultaneous assessment of drug activity against Leishmania intracellular amastigotes and their host cells Imported cutaneous leishmaniasis caused by Leishmania major in a Chinese laborer who worked in Saudi Arabia.Interventions for Old World cutaneous leishmaniasis.

P2860

Q26866450-9EC97212-35CD-4ED1-BA36-B1FF08F5448E Q28088410-9AAAA4F6-1909-41ED-9864-D7277A0D258A Q28271849-3712DB36-0447-42B7-AEDC-E5C0E0B60B74 Q29353558-2DD054B3-D3E3-495D-84A4-601F86CA04B2 Q34945204-A4126B4D-5019-41A3-924C-DCE86F5EB091 Q35180338-36911E59-5680-438D-B304-F9DC5E4B0C0B Q35187729-DC1E6435-1FCC-4508-B614-3AB3F674889D Q35708519-DB65F416-2E20-43B0-8FE1-F4E934F92C80 Q36086339-B5F768E4-06F0-40B7-964A-D48BA40B69C5 Q36455737-4525804A-C9CE-4C84-986F-A180635BD828 Q38156421-97E4A1F9-4CCF-48A0-8B31-4F28B2CAD548 Q38797460-2704471C-6C41-4E05-811C-573620FF3837 Q39548200-C4D57416-353E-4080-8380-0BD49EE695D6 Q42427702-67439D73-8EF8-487E-A248-B296D5260B09 Q46250558-430646F1-C225-4D0D-B200-87D1F905E818

P2860

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine

http://www.wikidata.org/entity/Q28478376

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dynamics of parasite clearance ...... ients treated with miltefosine

@ast

Dynamics of parasite clearance ...... ients treated with miltefosine

@en

Dynamics of parasite clearance ...... ients treated with miltefosine

@nl

type

label

Dynamics of parasite clearance ...... ients treated with miltefosine

@ast

Dynamics of parasite clearance ...... ients treated with miltefosine

@en

Dynamics of parasite clearance ...... ients treated with miltefosine

@nl

prefLabel

Dynamics of parasite clearance ...... ients treated with miltefosine

@ast

Dynamics of parasite clearance ...... ients treated with miltefosine

@en

Dynamics of parasite clearance ...... ients treated with miltefosine

@nl

P1433

Q28478376-9801FE56-2DE1-4188-8C1E-9A1647BA81B6

P1476

Q28478376-2847D648-E44D-4CCE-9D80-BE27CE42BB55

P2093

Q28478376-05761633-20F6-4031-A70C-F3D559365707

Q28478376-734B27B9-ADD5-441B-AFD6-BDB5497DEF68

Q28478376-8B9A03B5-48C5-463B-A130-F97DFE083F07

Q28478376-A37C7ABC-052A-4487-9257-D069735FEB1D

Q28478376-B2A0A002-11A4-47D4-BDDC-F0D25299E6E7

Q28478376-E5919F85-F2AD-4100-B1DF-86A29A05C7AF

P2860

Q28478376-20B39856-17B9-4C01-8B7F-D818556544E5

Q28478376-2B655E96-5A40-4B44-90E5-31FE6DF5B19A

Q28478376-51ED415B-638F-43E8-9748-E8E148889969

Q28478376-605D3DC8-EFC5-45F6-9CD9-ADB565348E4E

Q28478376-71DCC0CA-F42D-472C-AF44-4176A1071953

Q28478376-8EBE742C-78E4-41B5-A3F8-B7778E3334C6

Q28478376-97DA1023-F8D0-44E2-A5EF-DD6333850E9D

Q28478376-9CC1D89A-CFE4-4102-AF2C-5C58E4D47839

Q28478376-B6DDB8EA-4C77-41BC-95C1-D264F37171A3

Q28478376-D3E7D5B9-0872-4955-9B8E-3482EC19520F

P304

Q28478376-8232EF26-F841-4DA4-A913-740A6FAE3856

P31

Q28478376-460B2A51-86AE-4264-92F0-D2B77EB918C3

P3181

Q28478376-5EE69747-D236-4E3E-B585-2F79BE802B6E

P356

Q28478376-BD126F40-7A78-48C5-A22E-AE70455D79F2

P407

Q28478376-E06D3B94-3825-4724-938E-4FA0E913BBD5

P433

Q28478376-201412BA-1B19-4D93-A742-71ED7695A47E

P478

Q28478376-F575A10A-6776-4D46-97DB-3D19567386B6

P50

Q28478376-35C598FD-E4FE-490E-A634-1D08248F899F

P577

Q28478376-8126F180-BBD6-4525-9CD8-FCD185D735E7

P5875

Q28478376-14F01950-D45B-4000-A49E-ECFE16578CE2

P698

Q28478376-0E8DA30F-C87C-4938-9642-00D402C8276B

P921

Q28478376-A8AE6F7C-9C33-492A-B58A-D46F73B1AB43

P932

Q28478376-3C099048-0EE3-4F43-A6E7-525D13F1901D

P3181

P356

JOURNAL.PNTD.0001436

P1433

PLOS Neglected Tropical Diseases

P1476

Dynamics of parasite clearance ...... ients treated with miltefosine

@en

P2093

Gerard J Schoone

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Michèle van Vugt

http://www.w3.org/2001/XMLSchema#string

Peter J de Vries

http://www.w3.org/2001/XMLSchema#string

Pieter P A M van Thiel

http://www.w3.org/2001/XMLSchema#string

Ymkje Stienstra

http://www.w3.org/2001/XMLSchema#string

P2860

First cases of cutaneous leishmaniasis caused by Leishmania (Viannia) naiffi infection in Surinam.

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.

Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites.

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.

Visceral leishmaniasis: elimination with existing interventions.

Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis

Mucosal Leishmania infantum infection.

P304

e1436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1918519

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0001436

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Thomas P C Dorlo

P577

2011-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51899333

http://www.w3.org/2001/XMLSchema#string

P698

22180803

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

3236732

http://www.w3.org/2001/XMLSchema#string